Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): Two randomized, double-masked, phase 3, non-inferiority trials
97 Downloads
This activity is provided by Med Learning Group.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Copyright © 2019Med Learning Group. Built by Divigner. All Rights Reserved.
